Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and how it differs from traditional JAK inhibitors in autoimmune diseases like plaque psoriasis, psoriatic arthritis, SLE, and IBD.
Discover how peptide-based biologics are transforming autoimmune disease treatment by offering targeted, gut-selective immune modulation. Learn how vedolizumab’s peptide-engineered design blocks α4β7 integrin to treat ulcerative colitis and Crohn’s disease while preserving systemic immune function.